Lupin Secures US FDA Approval for Modafinil Tablets

Lupin Ltd receives FDA approval for 100 mg and 200 mg Modafinil tablets. The target market for the reference drug stands at USD 70.7 million annually.

Reader Takeaway: Expansion of US generic portfolio with a proven product, though facing established market competition.

What just happened

Lupin Ltd has successfully received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil tablets, USP. The approval covers both 100 mg and 200 mg strengths, which are bioequivalent to the reference listed drug, Provigil, currently marketed by Nuvo Pharmaceuticals (Ireland) DAC.

Why this matters

This approval allows Lupin to enter a specific therapeutic segment focused on improving wakefulness in adults suffering from conditions such as narcolepsy, obstructive sleep apnea (OSA), and shift work disorder. With the reference drug recording annual sales of approximately USD 70.7 million in the United States as of July 2026, the launch offers a new revenue stream for the company in the competitive US generics landscape.

Risks to watch

Investors should consider the typical risks associated with generic drug launches in the US, including pricing pressures from multiple market participants and the need for efficient supply chain execution to capture significant market share from established players.

Context metrics

• Reference drug: Provigil (Nuvo Pharmaceuticals)
• Market size: USD 70.7 million annual sales (IQVIA MAT Jul 2026)
• Approval date: September 04, 2026

What to track next

Watch for the official commercial launch date and Lupin's ability to maintain competitive pricing to gain market share in the US sleep-disorder therapeutic space.